Loading...
Market
What will be the outcome of current canine lifespan extension drug trials by the end of 2025?
2
Resolution / Starting Odds
Proven effective with significant lifespan extension • 25%
Proven effective with moderate lifespan extension • 25%
No significant effect on lifespan • 25%
Negative effects or halted trials • 25%
Official trial results or publications in scientific journals
Story
Scientists Develop Drugs, Including mTOR Inhibitor Rapamycin, to Extend Lifespan of Dogs with Implications for Human Longevity
Dec 27, 2024, 05:42 AM
Researchers are exploring new drugs aimed at extending the lifespan of dogs, which may have implications for human longevity. Current studies focus on the development of a pill that could prolong the lives of dogs, with scientists suggesting that similar effects might be applicable to humans. This follows the previous identification of the mTOR inhibitor, Rapamycin, as the only molecule rigorously proven to increase lifespan in healthy mice across various studies. The ongoing research into canine longevity could pave the way for advancements in human health and lifespan extension.
View original story
Similar markets
Significant tooth regrowth • 25%
No tooth regrowth • 25%
Minimal tooth regrowth • 25%
Moderate tooth regrowth • 25%
Negative results • 25%
Inconclusive results • 25%
Positive results • 25%
Trial halted • 25%
Negative efficacy and safety concerns • 25%
Positive efficacy and safety results • 25%
Positive efficacy, but safety concerns • 25%
Negative efficacy, but good safety • 25%
Moderate improvement • 25%
Significant improvement • 25%
No improvement • 25%
Worsening condition • 25%
Moderately effective • 25%
Highly effective • 25%
Not effective • 25%
Slightly effective • 25%
Funding Reallocated • 25%
Funding Increased • 25%
Funding Reduced • 25%
Funding Unchanged • 25%
Effective but not safe • 25%
Safe but not effective • 25%
Safe and effective • 25%
Neither safe nor effective • 25%
Negative results • 33%
Positive results • 33%
Inconclusive results • 34%
Funding reduced • 25%
Funding halted • 25%
Increased funding • 25%
No change in funding • 25%
Accidental attack • 25%
Negligence by owner • 25%
Other • 25%
Provocation by victim • 25%